Noah.AI Founder & CEO Yinan Wang Unveils Vision for Next-Gen AI Agent-Driven Biotech Company at CBA-China 2026 Annual Conference
Regor Therapeutics
Pharmaceutical R&D Developer
Chinese Biopharmaceutical Association - USA, China Chapter (CBA-China)Always committed to building a bridge connecting China and the U.S., integrating Eastern and Western academia and industry. Based on the global wave of biopharmaceutical innovation, focusing on industry pain points and future trends, we willMay 8-10InWuxi International Convention CenterHost2026 CBA-China Annual Conference in China。The conference was themed “Breaking the Deadlock, Symbiosis for a Healthy Future —— Addressing Global Changes, Building a New Ecosystem for Drug Innovation and Accessibility" as the theme, bringing together 260+ authoritative guests from home and abroad, 4000+ industry elites, and meticulously crafting 13 parallel forums, coveringEarly Development、Clinical Translation、Global Registration、CGT、ADC、AI Drug Discovery、Investment and Financing BDCovering all core sectors of the entire industrial chain. From in-depth analysis of cutting-edge technologies to interpretation of industry policies, from project matchmaking to capital cooperation, the comprehensive agenda showcases the global pharmaceutical innovation ecosystem, offering industry peers a high-standard, all-dimensional, and deeply insightful annual intellectual feast.
Noah AI CEO Wang YinanWill attend this conference and on the afternoon of May 9th "AI-Driven Structural Biology Revolution: Accelerating the Discovery of Innovative Drug Targets and Precision DevelopmentForum Keynote Speech Report:Building the Next Generation of Biotech Companies Driven by AI Agents。
Dr. Wang Yinuo, Founder/CEO of Noah AI, Beijing Science and Technology New Star, Suzhou Industrial Park Leading Entrepreneurial Talent. He graduated from Peking University with a bachelor's and Ph.D., and has served as the Head of Strategy and BD at Regor Therapeutics, and the Head of BD at Roche R&D Center China. As the first author, he has published multiple academic papers in top international journals such as Nature Biotechnology and Genome Biology, and is one of the pioneers in the field of global AI pharmaceuticals.
Conference Name:2026CBA-China Annual Conference in China
Hosted by:CBA-China (Chinese Biopharmaceutical Association - China Chapter)
Organizer:BioValley
Conference Time:May 8-10, 2026 (Friday-Sunday)
Venue:Wuxi International Conference Center
Conference Scale:4,000 people
Participants:Biopharmaceutical companies, project management and senior company executives, registration and overseas personnel, research institutes and hospitals, investment and consulting firms, factory construction and clean equipment.
Scan to Register
*From now until April 30, 2026, registration is free;Starting from May 1st, the conference registration fee will be 100 yuan per person;
*Share this post on your WeChat Moments, collect 18 likes, and redeem a meal voucher or a精美礼品on site. Limited quantity, first come, first served.
Preview of the Conference Agenda
CBA-China 2026
Agenda Unveiled with a Bang
CBA-China 2026
The specific agenda is subject to change; please refer to the final announcement...
Limited-time Free Registration Channel
(From now until April 30)
Scan the code to enter the conference group chat
(Note CBA2026)
| Business Cooperation
Stephen Sun
T: 15966587556
E: sunhx@biovalleyclub.com
| Academic Report
Seven Lu
T: 13641798663
E: tianyi.lu@biovalleyclub.com
| Media Cooperation/Conference Participation Inquiry
Abby Jiang
T: 18217659261
E: xiaolang.jiang@biovalleyclub.com
About CBA
Chinese American Biopharmaceutical Association(Chinese Biopharmaceutical Association-USA, abbreviated as CBA) was founded in 1995 and is the largest Chinese-American professional association in the biopharmaceutical field in the United States.
The primary mission of CBA is to serve as a bridge for cooperation between the United States and China in the biopharmaceutical field, promote comprehensive exchange among professionals in the pharmaceutical industries of both countries, and provide a favorable environment for the development and collaboration of biopharmaceutical companies and research institutions.
CBA members come from a variety of sources, including emerging technology companies in the U.S. and China, multinational pharmaceutical corporations, colleges and universities, research institutions, government pharmaceutical regulatory agencies, various support funds for research or industrial development, as well as professional organizations specializing in law and intellectual property. Over 80% of CBA members hold a Ph.D.
CBA has a good reputation internationally, with members遍布世界各地, including China, the United States, Europe, Canada, Australia, Singapore, and Japan. Currently, it has accumulated more than 10,000 individual members and over 1,000 corporate members.
CBA has a close relationship with the U.S. Food and Drug Administration (FDA). Many of its presidents have worked at the FDA and are familiar with international biopharmaceutical registration strategies and other regulations. It also has particularly strong ties with the University of Maryland, Johns Hopkins University, and its School of Medicine. Additionally, Jiangsu Province and Maryland State share a sister-state relationship.
Thanks to the following cooperative media for their support.
Click "Read the Original Text", sign up now~